Mpc-6827

Glioblastoma Multiforme

Myrexis Inc.Phase 2Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 54/ 100
Competitive Position: 81/ 100

Competitive context

47 Active assets in the Glioblastoma Multiforme cohort.

Asset / Sponsor	Phase	Rating
Irinotecan Beijing Sanbo Brain Hospital	Phase 2/3	BBB
Depatuxizumab Mafodotin AbbVie	Phase 3	BB
CARMUSTINE Leland Metheny	Phase 3	BB
Cintredekin Besudotox INSYS Therapeutics Inc	Phase 3	BB
Regorafenib Istituto Oncologico Veneto IRCCS	Phase 2/3	BB

View all 50 →

Same molecule, other indications

Mpc-6827 is also rated in:

Metastatic MelanomaDormant

CC

Indicative ·

46 / 100

Refractory Solid TumorsDormant

CC

Indicative ·

46 / 100

neurodegenerative diseaseDormant

CC

Indicative ·

43 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.